The Clinical Guidelines for Acute Uncomplicated Cystitis and Acute Uncomplicated Pyelonephritis

Total Page:16

File Type:pdf, Size:1020Kb

The Clinical Guidelines for Acute Uncomplicated Cystitis and Acute Uncomplicated Pyelonephritis ISSN 2465-8243(Print) / ISSN: 2465-8510(Online) https://doi.org/10.14777/uti.2017.12.2.55 Review Urogenit Tract Infect 2017;12(2):55-64 http://crossmark.crossref.org/dialog/?doi=10.14777/uti.2017.12.2.55&domain=pdf&date_stamp=2017-08-25 The Clinical Guidelines for Acute Uncomplicated Cystitis and Acute Uncomplicated Pyelonephritis Ki Ho Kim, Jae Heon Kim1, Seung-Ju Lee2, Hong Chung3, Jae Min Chung4, Jae Hung Jung5, Hyun Sop Choe2, Hun Choi6, Sun-Ju Lee7; The Committee of The Korean Association of Urogenital Track Infection and Inflammation Department of Urology, Dongguk University College of Medicine, Gyeongju, 1Department of Urology, Soonchunhyang University Seoul Hospital, Soonchunhyang University College of Medicine, Seoul, 2Department of Urology, St. Vincent’s Hospital, College of Medicine, The Catholic University of Korea, Suwon, 3Department of Urology, Konkuk University Chungju Hospital, Konkuk University School of Medicine, Chungju, 4Department of Urology, Pusan National University Yangsan Hospital, Yangsan, 5Department of Urology, Yonsei University Wonju College of Medicine, Wonju, 6Department of Urology, Korea University Ansan Hospital, Ansan,7Department of Urology, Kyung Hee University School of Medicine, Seoul, Korea To date, there has not been an establishment of guidelines for urinary tract Received: 10 April, 2017 infections, due to limited domestic data in Korea, unlike other North American and Revised: 25 April, 2017 Accepted: 25 April, 2017 European countries. The clinical characteristics, etiology, and antimicrobial susceptibility of urinary tract infections vary from country to country. Moreover, despite the same disease, antibiotic necessary to treat it may vary from country to country. Therefore, it is necessary to establish a guideline that is relevant to a specific country. However, in Korea, domestic data have been limited, and thus, guidelines considering the epidemiological characteristics pertaining specifically to Korea do Correspondence to: Ki Ho Kim not exist. Herein, describe a guideline that was developed by the committee of The http://orcid.org/0000-0001-8532-6517 Korean Association of Urogenital Tract Infection and Inflammation, which covers Department of Urology, Dongguk University College of Medicine, 87 Dongdae-ro, Gyeongju 38067, Korea only the uncomplicated urinary tract infections, as covering all parts in the first Tel: +82-54-770-8525, Fax: +82-54-770-8503 production is difficult. E-mail: [email protected] Keywords: Cystitis; Pyelonephritis; Urinary tract infections; Guideline This guideline is a reference for all patients; it may not be uniformly applicable to all patients. The clinical judgment should be made on a case-by-case Copyright 2017, Korean Association of Urogenital Tract Infection and Inflammation. All rights reserved. basis. This is an open access article distributed under the terms of the Creative Commons Attribution This guideline can be used for personal medical and Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits educational purposes, but it cannot be used for unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is commercial purposes or medical examination properly cited. purposes. INTRODUCTION from the most recently published Asian Association of UTI & STI (2016), Asian European Association of Urology (2014), 1. Background and Purpose Infectious Diseases Society of America (2011), and AMMI Urinary tract infections (UTIs) are one of the most Canada Guidelines Committee (2005). Major literature common infectious diseases. They are divided according published in Korea was searched using MEDLINE (January to the site of infection, presence or absence of symptoms, 1976 to September 2014), Embase (January 1985 to anatomical or functional abnormalities, and the presence September 2014), Cochrane Library (January 1987 to or absence of underlying diseases. The aim of this study September 2014), and KoreaMed (January 1958 to September was to develop a guideline for uncomplicated UTIs. 2014). We used the following keywords to search these databases: “cystitis,” “pyelonephritis,” “urinary tract 2. Methodology infections,” “necrotizing pyelonephritis,” “pyelonephritides,” The guideline presented here is based on the guidelines “Korea.” 55 56 Ki Ho Kim, et al. Clinical Guideline for Uncomplicated UTIs 3. Level of Evidence and Grade of the 1) Definition Recommendation Acute cystitis is a symptom characterized by lower urinary The level of evidence (LE) and the grade (GR) of tract symptoms, such as discomfort in the pubic area, as recommendation were accepted and used in accordance well as storage symptoms, such as pain during urination with the recent guidelines of the Oxford Center for without vaginal discharge, urinary frequency, urgency, and Evidence-Based Medicine. nocturia (LE: 2a, GR: B). There must be no risk factors that can cause complicated UTIs. 1) Level of evidence I: Evidence from at least one randomized controlled trial 2) Diagnosis II: Evidence obtained from at least one well-designed Urine dipstick test and urinary microscopy are widely controlled study without randomization used basic diagnostic methods [1]. Although urinalysis is III: Evidence obtained from well-designed non-experi- not mandatory, it is advised to perform a culture test, if mental studies, such as comparative studies, correla- acute pyelonephritis suspicion persists for 2-4 weeks or tion studies, and case reports there is recurrent cystitis symptoms (LE: 4, GR: B). In Korea, IV: Evidence obtained from expert committee reports, UTIs have a high rate of resistance to antibiotics. Acute opinions, or clinical experience of respected authorities cystitis is diagnosed when the urine (microscopy, more than 10 leukocytes) is observed or the colony is more than 2) Grade of recommendation 10,000 cfu/ml [2,3]. Additional diagnostic studies should A: Good evidence to support the recommendation for be considered when there is atypical symptoms, fever or against use without costovertebral angle tenderness, or no response B: Moderate evidence to support the recommendation to treatment (LE: 4, GR: B) [4,5]. for or against use C: Poor evidence to support the recommendation 3) Treatment Antibiotic treatment is recommended for patients with CLINICAL PRACTICE GUIDELINES BY acute cystitis because antibiotics have a significant DISEASE therapeutic benefit compared with placebos [6]. Since the resistance rate of E. coli to fluoroquinolone has already 1. Acute Uncomplicated Cystitis been reported to be greater than 20% in Korea, Acute uncomplicated cystitis is the most common UTI fluoroquinolone should be used carefully to empirically occurring mainly in adult women, especially sexually active treat simple UTIs [7,8]. Therefore, in the selection of young women and postmenopausal women. It is the most empirical antibiotics, it is important to consider the risk frequently encountered disease in primary medical factors of antibiotic resistance in patients, as well as the institutions, including urology, obstetrics, and gynecology. tendency to susceptibility of the area. Moreover, antibiotics More than half of healthy adult women visit the hospital should be altered in accordance with clinical features, and with acute uncomplicated cystitis at least once in their the duration of treatment should be adjusted in accordance lifetime. Escherichia coli is the most common organism with clinical features and persistence of symptoms. responsible for acute uncomplicated cystitis, followed by The criteria for determining empirical antibiotics are as Staphylococcus saprophyticus, Klebsiella pneumoniae, and follows: Proteus mirabilis. trimethoprim-sulfamethoxazole (TMP-SMX) • Clinical examination (no clinical symptoms of or fluoroquinolone was used as an empirical antibiotic. pyelonephritis such as high fever and flank pain, the However, fluoroquinolone-resistant strains and extended history of complicated UTIs such as diabetes) spectrum beta-lactamase (ESBL)-bacteria have increased, • Spectrum and susceptibility pattern of pathogenic requiring regional antibiotic resistance information and bacteria antibiotic guidelines. • Therapeutic patterns and antibiotic resistance rates in the community Urogenit Tract Infect Vol. 12, No. 2, August 2017 Ki Ho Kim, et al. Clinical Guideline for Uncomplicated UTIs 57 • Availability, tolerability, history of hypersensitivity to clavulanate 500 mg/125 mg oral twice a day, cefaclor 250 drugs, and side effects mg oral three times a day, cefdinir 100 mg oral three times • Cost a day, cefcapene pivoxil 100 mg oral three times a day, • Compliance to treatment and cefpodoxime proxetil 100 mg oral twice a day is A 3-day fluoroquinolone therapy has been widely used recommended (LE: 1, GR: A). and recommended as an empirical antibiotic treatment for In regions where the resistance rate of E. coli to TMP-SMX acute cystitis (LE: 1, GR: A). Ciprofloxacin 500 mg oral is less than 20%, it is possible to administer TMP-SMX bid (twice a day) for 3 days, ciprofloxacin SR 500 mg qd 160/800 mg twice daily for 5 days [12-14] (LE: 1b, GR: (once a day) for 3 days, and tosufloxacin 150 mg oral B). However, according to a recent multicenter antibiotic bid are recommended [9] (LE: 1b, GR: B). In Korea, resistance study for UTIs, 30% or more of E. coli identified fluoroquinolone is not approved to treat acute cystitis, which in patients with acute uncomplicated cystitis is resistant can lead to insurance-related problems. Due to
Recommended publications
  • Redalyc.Patterns of Antimicrobial Therapy in Acute Tonsillitis: a Cross
    Anais da Academia Brasileira de Ciências ISSN: 0001-3765 [email protected] Academia Brasileira de Ciências Brasil JOHN, LISHA J.; CHERIAN, MEENU; SREEDHARAN, JAYADEVAN; CHERIAN, TAMBI Patterns of Antimicrobial therapy in acute tonsillitis: A cross-sectional Hospital-based study from UAE Anais da Academia Brasileira de Ciências, vol. 86, núm. 1, enero-marzo, 2014, pp. 451-457 Academia Brasileira de Ciências Rio de Janeiro, Brasil Available in: http://www.redalyc.org/articulo.oa?id=32730090032 How to cite Complete issue Scientific Information System More information about this article Network of Scientific Journals from Latin America, the Caribbean, Spain and Portugal Journal's homepage in redalyc.org Non-profit academic project, developed under the open access initiative Anais da Academia Brasileira de Ciências (2014) 86(1): 451-457 (Annals of the Brazilian Academy of Sciences) Printed version ISSN 0001-3765 / Online version ISSN 1678-2690 http://dx.doi.org/10.1590/0001-3765201420120036 www.scielo.br/aabc Patterns of Antimicrobial therapy in acute tonsillitis: A cross-sectional Hospital-based study from UAE LISHA J. JOHN1, MEENU CHERIAN2, JAYADEVAN SREEDHARAN3 and TAMBI CHERIAN2 1Department of Pharmacology, Gulf Medical University, 4184, Ajman, United Arab Emirates 2Department of ENT, Gulf Medical College Hospital, 4184, Ajman, United Arab Emirates 3Statistical Support Facility, Centre for Advanced Biomedical Research and Innovation, Gulf Medical University, 4184, Ajman, United Arab Emirates Manuscript received on December 20, 2012; accepted for publication on October 14, 2013 ABSTRACT Background: Diseases of the ear, nose and throat (ENT) are associated with significant impairment of the daily life and a major cause for absenteeism from work.
    [Show full text]
  • AMR Surveillance in Pharma: a Case-Study for Data Sharingauthor by Professor Barry Cookson
    AMR Open Data Initiative AMR Surveillance in Pharma: a case-study for data sharingauthor by Professor Barry Cookson External Consultant to Project eLibrary • Division of Infection and Immunity, Univ. College London ESCMID• Dept. of Microbiology, © St Thomas’ Hospital Background of “90 day Project” Addressed some recommendations of the first Wellcome funded multi-disciplinary workshop (included Pharma Academia & Public Health invitees: 27thauthor July 2017 (post the Davos Declaration): by 1) Review the landscape of existing Pharma AMR programmes, their protocols,eLibrary data standards and sets 2) Develop a "portal" (register/platform) to access currently available AMR Surveillance data ESCMID Important ©to emphasise that this is a COLLABORATION between Pharma and others Overview of Questionnaire Content • General information - including name,author years active, countries, antimicrobials, microorganisms.by • Methodology - including accreditation, methodology for; surveillance, isolate collection, organism identification, breakpointseLibrary used, • Dataset - including data storage methodology, management and how accessed. ESCMID © 13 Company Responses author 7 by 3 3 eLibrary ESCMID © Structure of register Companies can have different ways of referring to their activities: We had to choose a consistent framework. author Companies Companyby 1 Programmes Programme A Programme B eLibrary Antimicrobials 1 2 3 4 5 company’s product comparator company’s product antimicrobials Programmes canESCMID contain multiple studies (e.g. Pfizer has© single
    [Show full text]
  • Consideration of Antibacterial Medicines As Part Of
    Consideration of antibacterial medicines as part of the revisions to 2019 WHO Model List of Essential Medicines for adults (EML) and Model List of Essential Medicines for children (EMLc) Section 6.2 Antibacterials including Access, Watch and Reserve Lists of antibiotics This summary has been prepared by the Health Technologies and Pharmaceuticals (HTP) programme at the WHO Regional Office for Europe. It is intended to communicate changes to the 2019 WHO Model List of Essential Medicines for adults (EML) and Model List of Essential Medicines for children (EMLc) to national counterparts involved in the evidence-based selection of medicines for inclusion in national essential medicines lists (NEMLs), lists of medicines for inclusion in reimbursement programs, and medicine formularies for use in primary, secondary and tertiary care. This document does not replace the full report of the WHO Expert Committee on Selection and Use of Essential Medicines (see The selection and use of essential medicines: report of the WHO Expert Committee on Selection and Use of Essential Medicines, 2019 (including the 21st WHO Model List of Essential Medicines and the 7th WHO Model List of Essential Medicines for Children). Geneva: World Health Organization; 2019 (WHO Technical Report Series, No. 1021). Licence: CC BY-NC-SA 3.0 IGO: https://apps.who.int/iris/bitstream/handle/10665/330668/9789241210300-eng.pdf?ua=1) and Corrigenda (March 2020) – TRS1021 (https://www.who.int/medicines/publications/essentialmedicines/TRS1021_corrigenda_March2020. pdf?ua=1). Executive summary of the report: https://apps.who.int/iris/bitstream/handle/10665/325773/WHO- MVP-EMP-IAU-2019.05-eng.pdf?ua=1.
    [Show full text]
  • WO 2010/025328 Al
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 4 March 2010 (04.03.2010) WO 2010/025328 Al (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 31/00 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, (21) International Application Number: CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, PCT/US2009/055306 DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (22) International Filing Date: HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, 28 August 2009 (28.08.2009) KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, (25) Filing Language: English NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, (26) Publication Language: English SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: 61/092,497 28 August 2008 (28.08.2008) US (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (71) Applicant (for all designated States except US): FOR¬ GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, EST LABORATORIES HOLDINGS LIMITED [IE/ ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, —]; 18 Parliament Street, Milner House, Hamilton, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, Bermuda HM12 (BM).
    [Show full text]
  • Computational Antibiotics Book
    Andrew V DeLong, Jared C Harris, Brittany S Larcart, Chandler B Massey, Chelsie D Northcutt, Somuayiro N Nwokike, Oscar A Otieno, Harsh M Patel, Mehulkumar P Patel, Pratik Pravin Patel, Eugene I Rowell, Brandon M Rush, Marc-Edwin G Saint-Louis, Amy M Vardeman, Felicia N Woods, Giso Abadi, Thomas J. Manning Computational Antibiotics Valdosta State University is located in South Georgia. Computational Antibiotics Index • Computational Details and Website Access (p. 8) • Acknowledgements (p. 9) • Dedications (p. 11) • Antibiotic Historical Introduction (p. 13) Introduction to Antibiotic groups • Penicillin’s (p. 21) • Carbapenems (p. 22) • Oxazolidines (p. 23) • Rifamycin (p. 24) • Lincosamides (p. 25) • Quinolones (p. 26) • Polypeptides antibiotics (p. 27) • Glycopeptide Antibiotics (p. 28) • Sulfonamides (p. 29) • Lipoglycopeptides (p. 30) • First Generation Cephalosporins (p. 31) • Cephalosporin Third Generation (p. 32) • Fourth-Generation Cephalosporins (p. 33) • Fifth Generation Cephalosporin’s (p. 34) • Tetracycline antibiotics (p. 35) Computational Antibiotics Antibiotics Covered (in alphabetical order) Amikacin (p. 36) Cefempidone (p. 98) Ceftizoxime (p. 159) Amoxicillin (p. 38) Cefepime (p. 100) Ceftobiprole (p. 161) Ampicillin (p. 40) Cefetamet (p. 102) Ceftoxide (p. 163) Arsphenamine (p. 42) Cefetrizole (p. 104) Ceftriaxone (p. 165) Azithromycin (p.44) Cefivitril (p. 106) Cefuracetime (p. 167) Aziocillin (p. 46) Cefixime (p. 108) Cefuroxime (p. 169) Aztreonam (p.48) Cefmatilen ( p. 110) Cefuzonam (p. 171) Bacampicillin (p. 50) Cefmetazole (p. 112) Cefalexin (p. 173) Bacitracin (p. 52) Cefodizime (p. 114) Chloramphenicol (p.175) Balofloxacin (p. 54) Cefonicid (p. 116) Cilastatin (p. 177) Carbenicillin (p. 56) Cefoperazone (p. 118) Ciprofloxacin (p. 179) Cefacetrile (p. 58) Cefoselis (p. 120) Clarithromycin (p. 181) Cefaclor (p.
    [Show full text]
  • Different Antibiotic Treatments for Group a Streptococcal Pharyngitis (Review)
    Different antibiotic treatments for group A streptococcal pharyngitis (Review) van Driel ML, De Sutter AIM, Keber N, Habraken H, Christiaens T This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in The Cochrane Library 2010, Issue 10 http://www.thecochranelibrary.com Different antibiotic treatments for group A streptococcal pharyngitis (Review) Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. TABLE OF CONTENTS HEADER....................................... 1 ABSTRACT ...................................... 1 PLAINLANGUAGESUMMARY . 2 BACKGROUND .................................... 2 OBJECTIVES ..................................... 3 METHODS ...................................... 3 RESULTS....................................... 5 DISCUSSION ..................................... 8 AUTHORS’CONCLUSIONS . 11 ACKNOWLEDGEMENTS . 11 REFERENCES ..................................... 12 CHARACTERISTICSOFSTUDIES . 16 DATAANDANALYSES. 43 Analysis 1.1. Comparison 1 Cephalosporin versus penicillin, Outcome 1 Resolution of symptoms post-treatment (ITT analysis). ................................... 45 Analysis 1.2. Comparison 1 Cephalosporin versus penicillin, Outcome 2 Resolution of symptoms post-treatment (evaluable participants)................................... 46 Analysis 1.3. Comparison 1 Cephalosporin versus penicillin, Outcome 3 Resolution of symptoms within 24 hours of treatment(ITTanalysis).. 47 Analysis 1.4. Comparison 1 Cephalosporin versus penicillin, Outcome
    [Show full text]
  • Antibiotics Therapy for Acute Bacterial Tonsillitis
    Pract Otol(Kyoto) 96:11;983~987, 2003 983 Antibiotics Therapy for Acute Bacterial Tonsillitis Shinya Takano and Hideki Kurihara Tokyo Women's Medical University Daini Hospital We reviewed the treatment of 96 patients with acute bacterial tonsillitis. Using multivariate analysis, we examined whether oral or intravenous administration of antibiotics (cephems, penicillin, other ƒÀ-lactams, tetracycline, clindamycin, new quinolones, and macrorides) had an influence on the treatment period. We found that the best class of oral antibiotics for acute bacterial tonsillitis was cefcapene pivoxil (CFPN-PI) and the best intravenous agent was sulbactum/cefoperazone (SBT/CPZ). Key words:retrospective study, acute bacterial tonsillitis, antibiotics, oral administration, intravenous injection Introduction tis such as infectious mononucleosis were excluded by Acute bacterial tonsillitis is one form of upper respira- blood tests. tory tract infection, in which bacteria invade the palatine We selected the administration of antibiotics at ran- tonsil and cause fever, sore throat, pus, and pain on swal- dom. lowing. The day when symptoms resolved and the WBC and In Europe and The United States, the drug of first CRP were normalized was defined as a "the day of cure" choice for acute bacterial tonsillitis is penicillin. How- and the treatment period defined as the interval between ever, there have been no reports on the first line treat- the first examination and this day. Using multivariate ment for acute tonsillitis in Japan, and only new analysis, we examined whether oral administration antibiotics have been examined for effectiveness against (levofloxacin (LVFX), clarithromycin (CAM), minocy- acute tonsillitis. cline (MIND), cefcapene pivoxil (CFPN-PI), ampicillin Penicillin is contraindicated in patients with infectious (ABPC), faropenem (FRPM), and no medication) or mononucleosis because it causes an exacerbation of their intravenous administration (cefepirome (CPR), clinda- rash1).
    [Show full text]
  • BMJ Open Is Committed to Open Peer Review. As Part of This Commitment We Make the Peer Review History of Every Article We Publish Publicly Available
    BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available. When an article is published we post the peer reviewers’ comments and the authors’ responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to. The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript. BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (http://bmjopen.bmj.com). If you have any questions on BMJ Open’s open peer review process please email [email protected] BMJ Open Pediatric drug utilization in the Western Pacific region: Australia, Japan, South Korea, Hong Kong and Taiwan Journal: BMJ Open ManuscriptFor ID peerbmjopen-2019-032426 review only Article Type: Research Date Submitted by the 27-Jun-2019 Author: Complete List of Authors: Brauer, Ruth; University College London, Research Department of Practice and Policy, School of Pharmacy Wong, Ian; University College London, Research Department of Practice and Policy, School of Pharmacy; University of Hong Kong, Centre for Safe Medication Practice and Research, Department
    [Show full text]
  • Revision of Precautions
    Published by Translated by Ministry of Health, Labour and Welfare Pharmaceuticals and Medical Devices Agency This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail. Revision of Precautions Cefmenoxime hydrochloride (preparations for otic and nasal use), chloramphenicol (solution for topical use, oral dosage form), tetracycline hydrochloride (powders, capsules), polymixin B sulfate (powders), clindamycin hydrochloride, clindamycin phosphate (injections), benzylpenicillin potassium, benzylpenicillin benzathine hydrate, lincomycin hydrochloride hydrate, aztreonam, amoxicillin hydrate, ampicillin hydrate, ampicillin sodium, potassium clavulanate/amoxicillin hydrate, dibekacin sulfate (injections), sultamicillin tosilate hydrate, cefaclor, cefazolin sodium, cefazolin sodium hydrate, cephalexin (oral dosage form with indications for otitis media), cefalotin sodium, cefixime hydrate, cefepime dihydrochloride hydrate, cefozopran hydrochloride, cefotiam hydrochloride (intravenous injections), cefcapene pivoxil hydrochloride hydrate, cefditoren pivoxil, cefdinir, ceftazidime hydrate, cefteram pivoxil, ceftriaxone sodium hydrate, cefpodoxime proxetil, cefroxadine hydrate, cefuroxime axetil, tebipenem pivoxil, doripenem hydrate, bacampicillin hydrochloride, panipenem/betamipron, faropenem sodium hydrate, flomoxef sodium, fosfomycin calcium hydrate, meropenem hydrate, chloramphenicol sodium succinate,
    [Show full text]
  • European Surveillance of Healthcare-Associated Infections in Intensive Care Units
    TECHNICAL DOCUMENT European surveillance of healthcare-associated infections in intensive care units HAI-Net ICU protocol Protocol version 1.02 www.ecdc.europa.eu ECDC TECHNICAL DOCUMENT European surveillance of healthcare- associated infections in intensive care units HAI-Net ICU protocol, version 1.02 This technical document of the European Centre for Disease Prevention and Control (ECDC) was coordinated by Carl Suetens. In accordance with the Staff Regulations for Officials and Conditions of Employment of Other Servants of the European Union and the ECDC Independence Policy, ECDC staff members shall not, in the performance of their duties, deal with a matter in which, directly or indirectly, they have any personal interest such as to impair their independence. This is version 1.02 of the HAI-Net ICU protocol. Differences between versions 1.01 (December 2010) and 1.02 are purely editorial. Suggested citation: European Centre for Disease Prevention and Control. European surveillance of healthcare- associated infections in intensive care units – HAI-Net ICU protocol, version 1.02. Stockholm: ECDC; 2015. Stockholm, March 2015 ISBN 978-92-9193-627-4 doi 10.2900/371526 Catalogue number TQ-04-15-186-EN-N © European Centre for Disease Prevention and Control, 2015 Reproduction is authorised, provided the source is acknowledged. TECHNICAL DOCUMENT HAI-Net ICU protocol, version 1.02 Table of contents Abbreviations ...............................................................................................................................................
    [Show full text]
  • Update on the Management of Antibiotic Allergy Bernard Yu-Hor Thong*
    Review Allergy Asthma Immunol Res. 2010 April;2(2):77-86. doi: 10.4168/aair.2010.2.2.77 pISSN 2092-7355 • eISSN 2092-7363 Update on the Management of Antibiotic Allergy Bernard Yu-Hor Thong* Department of Rheumatology, Allergy and Immunology, Tan Tock Seng Hospital, Singapore This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. Drug allergy to antibiotics may occur in the form of immediate or non-immediate (delayed) hypersensitivity reactions. Immediate reactions are usual- ly IgE-mediated whereas non-immediate hypersensitivity reactions are usually non-IgE or T-cell mediated. The clinical manifestations of antibiotic allergy may be cutaneous, organ-specific (e.g., blood dyscracias, hepatitis, interstitial nephritis), systemic (e.g., anaphylaxis, drug induced hypersen- sitivity syndrome) or various combinations of these. Severe cutaneous adverse reactions manifesting as Stevens Johnson syndrome or toxic epider- mal necrolysis (TEN) may be potentially life-threatening. The management of antibiotic allergy begins with the identification of the putative antibiot- ic from a detailed and accurate drug history, complemented by validated in-vivo and in-vitro allergological tests. This will facilitate avoidance of the putative antibiotic through patient education, use of drug alert cards, and electronic medical records with in-built drug allergy/adverse drug reaction prescription and dispensing checks. Knowledge of the evidence for specific antibiotic cross-reactivities is also important in patient education. Apart from withdrawal of the putative antibiotic, immunomodulatory agents like high-dose intravenous immunoglobulins may have a role in TEN.
    [Show full text]
  • E-Table 1. Drug Classification Category Name Generic Name
    BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance Supplemental material placed on this supplemental material which has been supplied by the author(s) Thorax e-Table 1. Drug classification Category Name Generic Name Antiplatelets clopidogrel, cilostazol, ticlopidine2, beraprost, beraprost–long acting, complavin Anticoagulants 2,3 dabigatran Statins1,2,3 atorvastatin2, simvastatin, pitavastatin, fluvastatin, pravastatin, rosuvastatin, amlodipine/atorvastatin Sodium channel blockers4,5† mexiletine, aprindine, cibenzoline Beta blocker acebutolol2 Class III antiarrhythmic drugs amiodarone1–6 Calcium channel blockers bepridil1, amlodipine/atorvastatin, telmisartan/amlodipine, valsartan/amlodipine, valsartan/cilnidipine, candesartan/amlodipine Angiotensin/converting enzyme enalapril inhibitor2‡ Thiazides trichlormethiazide, hydrochlorothiazide3,5, benzylhydrochlorothiazide/reserpine/carbazochrome, mefruside, telmisartan/hydrochlorothiazide, valsartan/hydrochlorothiazide, candesartan/hydrochlorothiazide, candesartan/trichlormethiazide, losartan/hydrochlorothiazide NSAIDs diclofenac2, celecoxib, loxoprofen, etodolac, nabumetone, pranoprofen Anti-rheumatics actarit, iguratimod, tofacitinib, penicillamine2–5, leflunomide1,3, sodium aurothiomalate2–6#, bucillamine Leukotriene receptor antagonist2* pranlukast 5-ASA mesalazine, salazosulfapyridine5 Tricyclic antidepressant Imipramine5, cromipramine, maprotiline Antiepileptics valproate, phenytoin2,3,5, ethotoin, carbamazepine2–5, zonisamide Interferon1,2,3
    [Show full text]